Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi And Genzyme: Do Big Pharmas And Orphan Drugs Fit Together?

Executive Summary

Big pharmas from Pfizer to GlaxoSmithKline are expanding their initiatives in niche disease areas, but if Sanofi-Aventis acquires Genzyme as it hopes, the French drug maker could soon emerge as an orphan drug leader
Advertisement

Related Content

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2010
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2010
Sanofi Turns The Screws On Genzyme
Pfizer Increases Commitment To Rare Diseases With New Research Unit
For Shire, Life After Adderall XR? Yes
Orphaned No Longer: Big Pharma Embraces Drugs for Niche Markets

Topics

Advertisement
UsernamePublicRestriction

Register

PS052590

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel